Results 151 to 160 of about 29,070 (238)

Crossing the barrier: nanomedicine as a frontier therapy for neuropathic Gaucher disease type 3. [PDF]

Ann Med Surg (Lond)
Saif M, Nasir A, Shafique S, Fatima M, Talha M.   +4 more
europepmc   +1 more source

Gaucher disease, state of the art and perspectives. [PDF]

J Intern Med
Camou F, Berger MG.
europepmc   +1 more source

My Case Against Uricase: a critical examination of hypotheses [PDF]

, 2019
O'Hearn, L Amber
core  

Constraint-based modelling of metabolic dysregulation in Gaucher disease: mitochondrial dysfunction and disrupted cholesterol homeostasis. [PDF]

Orphanet J Rare Dis
Liu Y, Luo X, Ranjbar S, Aerts JMFG, van der Lienden M, Dardis A, Fleming RMT.   +6 more
europepmc   +1 more source

Multidrug resistance and myelomonocytic leukaemia in gaucher's disease [PDF]

, 2003
Baker, R, Ganeshaguru, K, Krishnan, B, Mehta, AB, Richfield, L   +4 more
core  

Precision genomic profiling in Gaucher disease: insights from atypical presentations. [PDF]

Front Genet
Saith A, Ain NU, Ruan J, Kasaiyan M, Jain D, Israel G, Mehta S, Bamford NS, Nair S, Mistry PK.   +9 more
europepmc   +1 more source

Microbiome-gut-heart axis in cardiac complications of Gaucher disease type 3. [PDF]

Ann Med Surg (Lond)
Abedin ZU, Iqbal MU, Shahriar Z.
europepmc   +1 more source

Cytotoxic lymphocyte effector function is unaffected in patients with Gaucher disease. [PDF]

Front Immunol
Zou J, Noori T, Walterfang M, Szer J, Trapani JA, Voskoboinik I.   +5 more
europepmc   +1 more source

Unexpected Gaucher disease in a case of steroid-resistant nephrotic syndrome. [PDF]

Pediatr Nephrol
Gehad MH, Youssef DM, Mokhtar WA, Fathy MM, Gohary A.   +4 more
europepmc   +1 more source

An injectable hydrogel containing <i>N</i>-acetylglycine for the treatment of Gaucher disease. [PDF]

RSC Adv
Pradhan L, Manna S, Yadav AJ, Bajrang B, Chakraborty D, Bhagat K, Tripathi S, Parmar AS, Padhi AK, Mukherjee S.   +9 more
europepmc   +1 more source